Abstract:than mild ‘flu-like’ symptoms. One discontinued after 4 weeks because of ‘flu-like’ side-effects and another required reduction of the dose to 3 mu x 1 /week because of deterioration of pre-existing neutropenia. The general clinical status. spleen size, hirematological indices, peripheral blood granulocytemacrophage precursors (CFIJ-GM) and amino terminal procollagen peptide (which reflects the level of collagen synthesis) were monitored approximately every h weeks. There was no improvement or deterioration in the performance status of any evaluable patient except in the patient in acute phase whose disease progressed with increasing numbers of blast cells in the blood. Their haemoglobin levels remained unchanged and the transfusion requirements did not alter in the transfusion-dependent patients. The platelet counts were constant in four patients but decreased in two patients from 22 I to 1 3 0 x 1 Oy/l and from 2 5 3 to 108 x I OY/L respectively. All patients had splenomegaly at the start of their treatment. After 3 months of treatment the spleen had decreased in size in three patients (1 8 to 1 3 , h to 3 , 12 to 6 cm below the left costal margin) but had increased to its original size in all by 6 months despite continuing treatment. The peripheral blood CFU-GM numbers were evaluable in five patients. In three they decreased markedly to between 5% and 2Yj(, of the pre-treatment levels. Their numbers increased at least to pre-treatment levels within 2 months of stopping treatment. In two patients the CFU-GM levels did not change. In contrast, Anthony rL ul(1YY 1 ) detected transient elevations in the CFU-GM members during treatment. However, the extent ofvariability over time ofprogenitor numbers in untreated patients with myelofibrosis is not well documented. We conclude that at this dose level alfa-interferon. as a single agent. is not a useful treatment for this group of patients. It does, however. have a biological effect as evidenced by the transient decrease in spleen size in some patients, Trephine biopsy was not performed after treatment to access fibrosis because of the lack of clinical benefit or fall in the procollagen amino terminal peptide level. It remains possible that at higher doses or in combination with new cytokines. alfa-interferon might be beneficial. However, when it was reintroduced because of progressive splenomegaly at a dose of 3 mu x 5/week 3 months after stopping treatment in one patient whose spleen had initially responded, it had no effect on the splenic enlargement over a period of 2 months.

A 2009 Perspective on the 2004 American Thoracic Society Statement, “Respiratory Care of the Patient With Duchenne Muscular Dystrophy”

Study on Correlation between Changes in Coagulation and Fibrinolysis Related Factors and Incidence of Severe Pre-eclampsia

WNT pathways and upper limb anomalies

Analysis of perinatal coagulation function in preeclampsia

Maternal circulatory levels of procalcitonin, uric acid, and lipid profile in Early-onset preeclampsia and Late-onset preeclampsia

Changes of coagulation function and platelet parameters in preeclampsia and their correlation with pregnancy outcomes

Changes in Coagulation During Twin Pregnancies.

The Interaction Between Lipid Metabolism and Blood Coagulative-Fibrinolytic Activities in Preeclampsia and Normal Pregnancy

Variations of Coagulation Biochemical Markers in Normal Pregnant Women in Early and Late Pregnancy

A Perspective Study of Coagulative, Anticoagulative, Fibrinolyic and Hymodynamic Indexes in Normal Pregnancy

Predictive value of coagulation function and D-dimer for pregnancy outcome in pregnancy-induced hypertension

Alterations in Serum Adipocyte Fatty Acid Binding Protein and Retinol Binding Protein-4 in Normal Pregnancy and Preeclampsia.

Alternations of maternal and cord plasma hemostasis in preeclampsia before and after delivery.

Maternal Lipid Levels in Preeclampsia: Singleton Vs. Twin Pregnancies.

Changes of serum cardiotropin I and cystatin C in preeclampsia and significance thereof

Soluble precursors for CuInSe2, CuIn(1-x)Ga(x)Se2, and Cu2ZnSn(S,Se)4 based on colloidal nanocrystals and molecular metal chalcogenide surface ligands.

Imbalance of Serum T Helper 1- and 2-Type Cytokines in Preeclampsia and Gestational Hypertension

Predictive Value of Maternal Serum Biomarkers for Preeclampsia and Birth Weight: A Case-Control Study in Chinese Pregnant Women

ABSENCE OF GRAFT‐VERSUS‐LEUKAEMIA (GVL) EFFECT BY LEUCOCYTES TRANSFUSED: A PROSPECTIVE RANDOMIZED TRIAL IN ACUTE MYELOID LEUKAEMIA (AML) PATIENTS

Fibrinogen to albumin ratio, a novel serum indicator for evaluating the severity of preeclampsia: A single-center retrospective study

The Correlation Between Maternal Serum Sst2, IL‐33 and NT‐proBNP Concentrations and Occurrence of Pre‐eclampsia in Twin Pregnancies: A Longitudinal Study